A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies

Nuclear Medicine and Biology

Volumn 35, Issue 3, 2008, Pages 315-325

  Zeng, Zhizhen ^a   O'Brien, Julie A ^a   Lemaire, Wei ^a   O'Malley, Stacey S ^a   Miller, Patricia J ^a   Zhao, Zhijian ^a   Wallace, Michael A ^a   Raab, Conrad ^a   Lindsley, Craig W ^a,b   Sur, Cyrille ^a   Williams Jr , David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Autoradiography; Glycine; GlyT1; Schizophrenia

Indexed keywords

2 AMINO 4 CHLORO N (1 (4 PHENYL 1 (PROPYLSULFONYL)PIPERIDIN 4 YL)ETHYL)BENZAMIDE; 2 AMINO 4 CHLORO N (1 (4 PHENYL 1 (PROPYLSULFONYL)PIPERIDIN 4 YL)ETHYL)BENZAMIDE S 35; BENZAMIDE; GLYCINE TRANSPORTER 1; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; BINDING SITE; BRAIN MEMBRANE; BRAIN STEM; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; GRAY MATTER; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; NONHUMAN; RAT; SYNAPTOSOME; THALAMUS; WHITE MATTER;

ANIMALS; AUTORADIOGRAPHY; BENZAMIDES; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHORIOCARCINOMA; FEMALE; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MACACA MULATTA; PREGNANCY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; SULFUR RADIOISOTOPES; SYNAPTOSOMES; TISSUE DISTRIBUTION;

EID: 40749086417     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.12.002     Document Type: Article

References (36)

1. Betz H. Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron 5 4 (1990) 383-392
2. Bechade C., Sur C., and Triller A. The inhibitory neuronal glycine receptor. Bioessays 16 10 (1994) 735-744
3. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 6104 (1987) 529-531
4. Danysz W., and Parsons A.C. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50 4 (1998) 597-664
5. Berger A.J., Dieudonne S., and Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 80 6 (1998) 3336-3340
6. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 95 26 (1998) 15730-15734
7. Chen L., Muhlhauser M., and Yang C.R. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89 2 (2003) 691-703
8. Kinney G.G., Sur C., Burno M., Mallorga P.J., Williams J.B., Figueroa D.J., et al. The glycine transporter type 1 inhibitor N-[3-(4(-fluorophenyl)-3-(4(-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23 20 (2003) 7586-7591
9. Smith K.E., Borden L.A., Hartig P.R., Branchek T., and Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8 5 (1992) 927-935
10. Zafra F., Aragon C., Olivares L., Danbolt N.C., Gimenez C., and Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J Neurosci 15 5 Pt 2 (1995) 3952-3969
11. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., et al. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60 6 (2001) 1414-1420
12. 3H]-(N-[3-(4(-fluorophenyl)-3-(4(phenylphenoxy)propyl])sarco sine. Neuropharmacology 45 5 (2003) 585-593
13. Heresco-Levy U. N-Methyl-d-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int J Neuropsychopharmacol 3 3 (2000) 243-258
14. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
15. Le Pen G., Kew J., Alberati D., Borroni E., Heitz M.P., and Moreau J.L. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 54 11 (2003) 1162-1170
16. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151 8 (1994) 1234-1236
17. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., and Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169 5 (1996) 610-617
18. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56 1 (1999) 29-36
19. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55 2 (2004) 165-171
20. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 11 (1998) 1081-1089
21. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55 5 (2004) 452-456
22. Vandenberg R.J., and Aubrey K.R. Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 5 4 (2001) 507-518
23. Lindsley C.W., Zhao Z., Leister W.H., O'Brien J., Lemaire W., Williams Jr. D.L., et al. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. Chem Med Chem 1 8 (2006) 807-811
24. Limbird L.E. Cell surface receptors: a short course on theory and methods (1986), Martinus Nijhoff Publishing, Boston
25. Zhao Z., O'Brien J.A., Lemaire W., Williams Jr. D.L., Jacobson M.A., Sur C., et al. Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)be nzamides. Bioorg Med Chem Lett 16 23 (2006) 5968-5972
26. Hayden T., Ravert W.B.M., Klitenick M.A., Wong D.F., and Dannals R.F. Radiosynthesis of ligand for studying the glycine transporter: [11C]ALX-5407. J Labelled Compd Radiopharm 44 (2001) 241-246
27. 3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett 13 7 (2003) 1291-1292
28. Adams R.H., Sato K., Shimada S., Tohyama M., Puschel A.W., and Betz H. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J Neurosci 15 3 Pt 2 (1995) 2524-2532
29. Jursky F., Tamura S., Tamura A., Mandiyan S., Nelson H., and Nelson N. Structure, function and brain localization of neurotransmitter transporters. J Exp Biol 196 (1994) 283-295
30. Cubelos B., Gimenez C., and Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15 4 (2005) 448-459
31. Danglot L., Rostaing P., Triller A., and Bessis A. Morphologically identified glycinergic synapses in the hippocampus. Mol Cell Neurosci 27 4 (2004) 394-403
32. Atack J.R., Pike A., Clarke A., Cook S.M., Sohal B., McKernan R.M., et al. Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708. Drug Metab Dispos 34 5 (2006) 887-893
33. 3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 51 1 (2006) 168-172
34. Assie M.B., Dominguez H., Consul-Denjean N., and Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373 6 (2006) 441-450
35. Wee S., Carroll F.I., and Woolverton W.L. A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology 31 2 (2006) 351-362
36. 3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbox ylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomography. J Pharmacol Exp Ther 320 3 (2007) 1030-1037